Login to Your Account

Alkermes jolted by dual phase III misses in ALKS 5461 depression program

By Michael Fitzhugh
Staff Writer

Thursday, January 21, 2016

Missed efficacy endpoints in two phase III trials of Alkermes plc's lead candidate, the once-daily depression medicine ALKS 5461, dragged company shares (NASDAQ:ALKS) down by 44.2 percent.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription